Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Sture, Lindegren"'
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Background A significant challenge in cancer therapy lies in eradicating hidden disseminated tumor cells. Within Nuclear Medicine, Targeted Alpha Therapy is a promising approach for cancer treatment tackling disseminated cancer. As tumor siz
Externí odkaz:
https://doaj.org/article/278aba369eb9421986b55d1c8c570cee
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-211 is one of the most promising candidate nuclides. Astatine-211 can be produced in medium energy cyclotrons by alpha particle bombardment of natural bism
Externí odkaz:
https://doaj.org/article/84425675626342489a67157e2b2ecff5
Autor:
Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut Smerud, Stig Palm
Publikováno v:
Frontiers in Medicine, Vol 9 (2023)
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of
Externí odkaz:
https://doaj.org/article/d22308bdcbb6401cb0e87576be06c2cb
Autor:
Emanuel Sporer, Christian B. M. Poulie, Sture Lindegren, Emma Aneheim, Holger Jensen, Tom Bäck, Paul J. Kempen, Andreas Kjaer, Matthias M. Herth, Andreas I. Jensen
Publikováno v:
Journal of Nanotheranostics, Vol 2, Iss 4, Pp 196-207 (2021)
Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At). However, 211At-carbon bonds are notoriously unstable in vivo and no chelators are availa
Externí odkaz:
https://doaj.org/article/fc6d21baaf7241e9801fd9856d9fa10c
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 595 (2023)
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has an affinity
Externí odkaz:
https://doaj.org/article/59623e6c974e4e15996073c8c88b1448
Autor:
Tom A. Bäck, Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, Stig Palm, Per Albertsson, Jan-Erik Damber, Anna M. Wu, Karin Welén
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-12 (2020)
Abstract Purpose Targeted alpha therapy (TAT) is a promising treatment for micrometastatic and minimal residual cancer. We evaluated systemic α-radioimmunotherapy (α-RIT) of metastatic castration-resistant prostate cancer (mCRPC) using the α-parti
Externí odkaz:
https://doaj.org/article/cb79622cfe444d258013759e1047e094
Autor:
Stig Palm, Tom Bäck, Emma Aneheim, Andreas Hallqvist, Ragnar Hultborn, Lars Jacobsson, Holger Jensen, Sture Lindegren, Per Albertsson
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100873- (2021)
Introduction: Antibodies labeled with alpha-emitter astatine-211 have previously shown effective in intraperitoneal (i.p.) treatments of ovarian cancer. In the present work we explore the use of investigational farletuzumab, aimed at the folate recep
Externí odkaz:
https://doaj.org/article/8b5b24b491734c9ea4620f2acfedf29f
Autor:
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm, Lars Jacobsson, Alfred Morgenstern, Frank Bruchertseifer, Per Albertsson, Sture Lindegren
Publikováno v:
EJNMMI Research, Vol 7, Iss 1, Pp 1-8 (2017)
Abstract Background The aim of this study was to compare the therapeutic efficacy of two different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperiton
Externí odkaz:
https://doaj.org/article/9db342e805264a548da9e9feb6f45337
Autor:
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson
Publikováno v:
Journal of Nuclear Medicine. 64:165-172
Autor:
Holger Jensen, Matthias M. Herth, Emma Aneheim, Andreas Kjaer, Paul J. Kempen, Andreas Tue Ingemann Jensen, Emanuel Sporer, Tom Bäck, Sture Lindegren, Christian B. M. Poulie
Publikováno v:
Sporer, E, Poulie, C B M, Lindegren, S, Aneheim, E, Jensen, H, Bäck, T, Kempen, P J, Kjaer, A, Herth, M M & Jensen, A I 2021, ' Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy ', Journal of Nanotheranostics, vol. 2, no. 4, pp. 196-207 . https://doi.org/10.3390/jnt2040012
Journal of Nanotheranostics, Vol 2, Iss 12, Pp 196-207 (2021)
Capital Region of Denmark
Journal of Nanotheranostics, Vol 2, Iss 12, Pp 196-207 (2021)
Capital Region of Denmark
Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At). However, 211At-carbon bonds are notoriously unstable in vivo and no chelators are availa